OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100
Debt
Debt-to-Equity Ratio0.03
Current Ratio1.05
Quick Ratio0.90
Price-To-Earnings
Trailing P/E Ratio-19.34
Forward P/E Ratio-23.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 billion
Price / Sales2.94
Cash FlowN/A
Price / CashN/A
Book Value$3.37 per share
Price / Book1.66
Profitability
EPS (Most Recent Fiscal Year)($0.29)
Net Income$-308,870,000.00
Net Margins-31.73%
Return on Equity-9.32%
Return on Assets-6.81%
Miscellaneous
Employees6,030
Outstanding Shares559,770,000
Market Cap$3.03 billion
Opko Health (NASDAQ:OPK) Frequently Asked Questions
What is Opko Health's stock symbol?
Opko Health trades on the NASDAQ under the ticker symbol "OPK."
How were Opko Health's earnings last quarter?
Opko Health Inc. (NASDAQ:OPK) released its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.06. The biotechnology company earned $263.69 million during the quarter, compared to analysts' expectations of $260.37 million. Opko Health had a negative net margin of 31.73% and a negative return on equity of 9.32%. View Opko Health's Earnings History.
When is Opko Health's next earnings date?
What price target have analysts set for OPK?
4 brokers have issued twelve-month target prices for Opko Health's shares. Their forecasts range from $7.00 to $20.00. On average, they expect Opko Health's stock price to reach $12.50 in the next year. This suggests a possible upside of 122.8% from the stock's current price. View Analyst Price Targets for Opko Health.
What is the consensus analysts' recommendation for Opko Health?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health.
What are Wall Street analysts saying about Opko Health stock?
Here are some recent quotes from research analysts about Opko Health stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $20 for OPK shares post a 2Q18 EPS beat. We continue to think that the long-term sales and earnings potential of OPK’s business is underappreciated and that upward earnings revisions in 2019+ to levels not reflected in consensus expectations should drive the stock higher. We expect upward earnings revisions to come from the uptake of Rayaldee, commercialization of OPK’s branded drug pipeline, and BioReference sales growth and margin expansion." (8/7/2018)
- 2. According to Zacks Investment Research, "OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. " (5/25/2018)
- 3. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline." (5/9/2018)
Are investors shorting Opko Health?
Opko Health saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 77,265,139 shares, an increase of 5.3% from the July 13th total of 73,367,143 shares. Based on an average daily volume of 7,841,236 shares, the days-to-cover ratio is currently 9.9 days. Currently, 23.8% of the company's stock are sold short. View Opko Health's Current Options Chain.
Who are some of Opko Health's key competitors?
Some companies that are related to Opko Health include Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Catalent (CTLT).
Who are Opko Health's key executives?
Opko Health's management team includes the folowing people:
- Dr. Philip Frost, Chairman & CEO (Age 82)
- Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 71)
- Mr. Adam E. Logal, Sr. VP & CFO (Age 40)
- Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 58)
- Ms. Kate Inman, Gen. Counsel & Sec. (Age 45)
Has Opko Health been receiving favorable news coverage?
News stories about OPK stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Opko Health earned a media and rumor sentiment score of 0.16 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.69 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Opko Health.
Who are Opko Health's major shareholders?
Opko Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.28%), Dimensional Fund Advisors LP (0.63%), Schwab Charles Investment Management Inc. (0.43%), Canada Pension Plan Investment Board (0.40%), Harel Insurance Investments & Financial Services Ltd. (0.39%) and IFP Advisors Inc (0.39%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.
Which major investors are selling Opko Health stock?
OPK stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Harel Insurance Investments & Financial Services Ltd., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, State Board of Administration of Florida Retirement System, Stevens Capital Management LP, California Public Employees Retirement System, Brandes Investment Partners LP and Virtu Financial LLC. View Insider Buying and Selling for Opko Health.
Which major investors are buying Opko Health stock?
OPK stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., RK Asset Management LLC, Schwab Charles Investment Management Inc., Canada Pension Plan Investment Board, ING Groep NV, Bank of New York Mellon Corp, Chicago Equity Partners LLC and GSA Capital Partners LLP. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.
How do I buy shares of Opko Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opko Health's stock price today?
One share of OPK stock can currently be purchased for approximately $5.61.
How big of a company is Opko Health?
Opko Health has a market capitalization of $3.03 billion and generates $1.07 billion in revenue each year. The biotechnology company earns $-308,870,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Opko Health employs 6,030 workers across the globe.
How can I contact Opko Health?
Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for Opko Health (NASDAQ OPK)
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
